Literature DB >> 10025740

The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.

M Amagai1, K Tsunoda, D Zillikens, T Nagai, T Nishikawa.   

Abstract

BACKGROUND: Some patients with pemphigus vulgaris (PV) have mucous membrane erosions with minimal skin involvement (mucosal dominant type), and others show extensive skin blisters and erosions in addition to mucous membrane involvement (mucocutaneous type). Patients with pemphigus foliaceus (PF) show only skin involvement.
OBJECTIVE: The purpose of this study is to determine whether there is a difference in autoantibody profile among mucosal dominant PV, mucocutaneous PV, and PF.
METHODS: Antibody titer against desmoglein 1 (Dsg 1) and desmoglein 3 (Dsg3) were measured with enzyme-linked immunosorbent assay using recombinant Dsg1 and Dsg3. Sera were obtained during clinically active disease from 24 patients with mucosal dominant PV, 20 with mucocutaneous PV, and 23 with PF.
RESULTS: All sera samples from patients with mucosal dominant PV sera were negative against Dsgl but positive against Dsg3. All sera samples from those with mucocutaneous PV were positive against both Dsg1 and Dsg3. All sera samples from patients with PF were positive against Dsg1, but negative against Dsg3.
CONCLUSION: Each subtype has its own anti-Dsg autoantibody profile, indicating that the clinical phenotype of pemphigus is defined by the autoantibody profile.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025740     DOI: 10.1016/s0190-9622(99)70183-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  61 in total

1.  Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses.

Authors:  N Sami; K C Bhol; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  The problems and promises of research into human immunology and autoimmune disease.

Authors:  Bart O Roep; Jane Buckner; Stephen Sawcer; Rene Toes; Frauke Zipp
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

3.  Relationship between target antigens and major histocompatibility complex (MHC) class II genes in producing two pathogenic antibodies simultaneously.

Authors:  L R Zakka; D B Keskin; P Reche; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2010-11       Impact factor: 4.330

4.  p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris.

Authors:  Xuming Mao; Yasuyo Sano; Jin Mo Park; Aimee S Payne
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

Review 5.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

6.  [Erosions of the mouth mucosa].

Authors:  G Mühlmeier; M Tisch; R O Bredlich; R U Peter; H Maier
Journal:  HNO       Date:  2002-08       Impact factor: 1.284

7.  [Transformation of pemphigus foliaceus into pemphigus vulgaris].

Authors:  C Mühlhoff; M Megahed
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

8.  Biphasic activation of p38MAPK suggests that apoptosis is a downstream event in pemphigus acantholysis.

Authors:  Hua En Lee; Paula Berkowitz; Puneet S Jolly; Luis A Diaz; Michael P Chua; David S Rubenstein
Journal:  J Biol Chem       Date:  2009-03-07       Impact factor: 5.157

9.  Absence of human herpesvirus 8 in pemphigus and bullous pemphigoid.

Authors:  Anjela Galan; Pei Hui; Jennifer M McNiff
Journal:  Int J Clin Exp Pathol       Date:  2009-01-30

Review 10.  Effects of acute and chronic inflammation on B-cell development and differentiation.

Authors:  Derek Cain; Motonari Kondo; Huaiyong Chen; Garnett Kelsoe
Journal:  J Invest Dermatol       Date:  2009-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.